Editorial Note: This post by DG follows up on last week’s Robbie’s Tourette Syndrome Story and continues a series begun a year ago looking at the effects of aripiprazole on Tourette Syndrome Abilify, Tourette Syndrome and Me. As mentioned last week, the key point is not just drug induced adverse effects but the ability of […]

Editorial Note: This post by DG continues a series begun a year ago looking at the effects of aripiprazole on Tourette Syndrome Abilify, Tourette Syndrome and Me. The key point here is not just the effect of a drug to trigger effects but the ability of someone who has the disorder and takes the treatment […]

Written by Johanna Ryan, May 9, 2015 This column is partly a report on the marketing of Abilify, the atypical antipsychotic that has become America’s best-selling drug. It’s also an appeal for advice and feedback from the RxISK and Mad in America communities, and a call for some brainstorming about strategy. The plans laid out […]

Editorial Note: This post follows on from one of the most compelling RxISK stories ever – Abilify, Tourette Syndrome and Me, posted last week. It comes in two parts. The first by last week’s author and the second by the series editor, Johanna Ryan. In our efforts to get our story told, raise awareness about […]